This special issue of Translational Andrology and Urology (TAU), therefore, is focused on “genetics and biomarker in bladder cancer for optimized clinical decision-making and improved outcomes”. As editor, I strove to present a current, state-of-the-art and global perspective of the genetically heterogeneity in UCB as well as different approaches, possibilities and implications of biomarkers in UCB for current and future clinical decision-making, management and research. Established national and international experts as well as rising stars were invited to contribute to this comprising and timely subject of major importance for our daily practice and future clinical trial design.
Guest Editor
Michael Rink, MD, FEBU
Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany